Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02049541 · ClinicalTrials.gov registry record · Phase 1
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
A Phase 1 study, sponsored by Kami Maddocks, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02049541 is a Phase 1 study that has completed, run by Kami Maddocks, MD. The registered enrollment target is 18 participants.
The verdict
NCT02049541, a Phase 1 study, has completed, sponsored by Kami Maddocks, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This phase I clinical trial studies the side effects and the best dose of phosphatidylinositol-3-kinase (PI3K) inhibitor BKM120 when given together with rituximab in treating patients with relapsed or refractory low-grade B-cell lymphoma. PI3K inhibitor BKM120 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving PI3K inhibitor BKM120 with rituximab may be an effective treatment for B-cell lymphoma.
Interventions
- BIOLOGICAL rituximab
- OTHER Correlative studies
- DRUG PI3K inhibitor BKM120
- OTHER Pharmacodynamics
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2014-07-21 |
| Est. Completion | 2019-04-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02049541
The ClinicalTrials.gov registry entry for NCT02049541 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kami Maddocks, MD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which rituximab is the first listed.
NCT02049541 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02049541 about?
NCT02049541 is a clinical study titled "Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma". This phase I clinical trial studies the side effects and the best dose of phosphatidylinositol-3-kinase (PI3K) inhibitor BKM120 when given together with rituximab in treating patients with relapsed or refractory low-grade B-cell lymphoma. PI3K inhibitor BKM120 may stop the growth of cancer cells by ...
What is the current status of trial NCT02049541?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2014-07-21. Estimated completion is 2019-04-09.
What interventions are being tested in trial NCT02049541?
The interventions under investigation include: rituximab (BIOLOGICAL), Correlative studies (OTHER), PI3K inhibitor BKM120 (DRUG), Pharmacodynamics (OTHER).
Who is sponsoring clinical trial NCT02049541?
This trial is sponsored by Kami Maddocks, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.